|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, anti-inflammatory and anti-oxidant effects
Description: Defined as the time from randomization to an improvement of two points (from the status of randomization) on seven category ordinal scale or live discharge from the hospital, whichever comes first.Measure: Time to clinical improvement Time: 7-28 days
Description: Clinical status as assessed with the seven-category ordinal scale on days 7 and 14Measure: Clinical outcome Time: 7-14 days
Description: Time in days patient was intubatedMeasure: Duration of Mechanical Ventilation Time: Randomization till hospital discharge or death whichever came first, assessed up to 28 days
Description: Total days of hospitalizationMeasure: Hospitalization Time: Randomization till hospital discharge or death whichever came first, assessed up to 28 days
Description: number of days patient remained with positive RT-PCR SARS-CoV-2 swabMeasure: Virologic Response Time: Randomization till discharge, up to 28 days
Description: Any adverse events whether related to medication or notMeasure: Adverse events Time: Randomization till hospital discharge, up to 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports